Table 4.
MicroRNAs with implications in therapy.
| MicroRNA | Sample source | Karyotype association | Expression | Function | Target | Implication | Reference |
|---|---|---|---|---|---|---|---|
| MiR-22 | Bone marrow/Plasma | Upregulated | Role in HSC renewal | TET2 | Prognosis/Therapeutic target | (14) | |
| MiR-34a | Peripheral blood | Upregulated | Regulator of proliferation | DOCK8, FGD4, Rac1, c-Fos, Cdc42-WASP-Arp2/3 pathway | Potential therapeutic target | (43–45) | |
| MiR-150 | Bone marrow | MDS with del(5q) | Upregulated | Role in erythropoiesis, megakaryopoiesis | MYB, BC200 | Potential therapeutic target | (34) |
| MiR-765 | Bone marrow | Upregulated | Apoptosis | PLP2 | Potential therapeutic target | (40) | |
| MiRs in DLK1-DIO3 genomic region | Bone marrow | Upregulated | Apoptosis, regulation of HSPC differentiation | MEG3-DMR | Prognostic markers, Therapy response markers | (22) | |
| MiR-125b | Bone marrow | t(2;11)(p21;q23) | Upregulated | Block the myelomonocytic differentiation | Potential therapeutic target | (64) | |
| MiR-218 | Downregulated | Role in tumorigenesis | SLIT2/3 | Prognostic marker, Potential therapeutic target | (23) | ||
| MiR-595 | Bone marrow | Chromosome 7 abnormalities | Downregulated | Cellular proliferation, apoptosis, and defective ribosomal biogenesis | RPL27A | Potential therapeutic target | (65) |
| MiR-597 | Upregulated | Apoptosis | FOSL2 | Potential therapeutic target | (59) | ||
| MiR-192 | Bone marrow/plasma | Upregulated | Tumor suppressor | BCL2, TP53, and TGF-beta | Therapy response | (86) | |
| MiR-126 | Bone marrow | Downregulated | DNMT1 | Azacitidine resistance | (93) | ||
| MiR-4755 | Upregulated | CDKN2B | Decitabine resistance | (95) | |||
| MiR-92a | Exosomes | Upregulated | PTEN | Ara-C resistance | (96) | ||
| MiR-21 | Bone marrow | Upregulated | SMAD7, TGF-b | Therapeutic target | (97) | ||
| MiR-146a | TRAF6, IRAK1 | Therapeutic target | (98) |